These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1085500)

  • 1. Importance of protease inhibition in studies on purified factor VIII (antihaemophilic factor).
    Beck EA; Bachmann P; Barbier P; Furlan M
    Thromb Haemost; 1976 Feb; 35(1):186-90. PubMed ID: 1085500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution to the isolation and study of the molecular weight of human factor VIII].
    Mazurier C; Parquet-Gernez A; Goudemand M; Montreuil J
    Pathol Biol (Paris); 1975 Dec; 23 suppl():11-6. PubMed ID: 57588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.
    Switzer ME; McKee PA
    J Clin Invest; 1976 Apr; 57(4):925-37. PubMed ID: 1084890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of proteases in AHF concentrates: effect on factor VIII:von Willebrand protein as assessed by high-pressure gel permeation chromatography.
    Orthner CL
    J Lab Clin Med; 1984 Nov; 104(5):816-28. PubMed ID: 6436416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation of factor VIII in the presence of proteolytic inhibitors.
    Sussman II; Weiss HJ
    Thromb Haemost; 1978 Oct; 40(2):316-25. PubMed ID: 310586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical and chemical properties of normal and haemophilic factor VIII.
    Vermylen J
    Pathol Biol (Paris); 1975 Dec; 23 suppl():5-10. PubMed ID: 772559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation.
    Hoyer LW; Trabold NC
    J Lab Clin Med; 1981 Jan; 97(1):50-64. PubMed ID: 6778941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Structural model of factor VIII complex].
    Furlan M; Beck EA
    Schweiz Med Wochenschr; 1976 Oct; 106(40):1378. PubMed ID: 1006260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction of the factor VIII/von Willebrand factor complex with hematin.
    Green D; Furby FH; Berndt MC
    Thromb Haemost; 1986 Dec; 56(3):277-82. PubMed ID: 3105105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
    Koedam JA; Meijers JC; Sixma JJ; Bouma BN
    J Clin Invest; 1988 Oct; 82(4):1236-43. PubMed ID: 2971673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factor VIII (coagulation activity VIII:C, antigen concentration VIIIR:Ag and von Willebrand factor) in patients with clinically expected intravascular coagulation].
    Tran TH; Lämmle B; Marbet UA; Ritz R; Marbet GA; Duckert F
    Schweiz Med Wochenschr; 1981 Oct; 111(41):1542-3. PubMed ID: 6797063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purified complex of factor VIII coagulant moiety and phospholipid: high factor VIII coagulant activity in factor VIII inhibitor plasma.
    Muntean W
    Wien Klin Wochenschr; 1984 Nov; 96(22):829-32. PubMed ID: 6442046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII procoagulant protein.
    Zimmerman TS; Fulcher CA
    Clin Haematol; 1985 Jun; 14(2):343-58. PubMed ID: 3930116
    [No Abstract]   [Full Text] [Related]  

  • 15. Multimers of von Willebrand antigen in therapeutic factor VIII concentrates.
    Vukovich TC
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):831-40. PubMed ID: 2436998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of neutral proteases from human leukocytes on structure and biological properties of human factor VIII.
    Kopeć M; Bykowska K; Lopaciuk S; Jelenska M; Kaczanowska J; Sopata I; Wojtecka E
    Thromb Haemost; 1980 Jul; 43(3):211-7. PubMed ID: 6256922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
    Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
    Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand activity of low molecular weight human Factor VIII increases by binding to gold granules.
    Furlan M; Perret BA; Beck EA
    Thromb Haemost; 1981 Jun; 45(3):242-6. PubMed ID: 6792738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.